Trading in any company will carry risks though - and especially with Biotech companies at the cutting edge of research. I think the risks you listed are valid but these are known I would have thought.
IMU is cashed up and there is an elevated volume in trading. Good management decisions have put IMU in a very robust position for a Biotech that is essentially in an advanced research stage.
Imugene now valued at $3 Billion. Hello ASX200!!, page-89
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.001(1.82%) |
Mkt cap ! $396.8M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.6¢ | 5.4¢ | $443.4K | 8.072M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 3056419 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 120000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |